Among these prognostic factors, the expression of hormone receptor is particularly useful for guiding treatment decisions in clinical oncology; the presence of Ki-67 LI, a molecular marker of tumor proliferation, has been linked to a poorer prognosis in breast cancer [2,3,4,5,6,7,15]. Here, NR4A1 is linked to breast carcinoma.